Pfizer Declares First-Quarter 2025 Dividend

Rhea-AI Summary

Pfizer (NYSE: PFE) has announced an increase in its quarterly cash dividend to $0.43 per share for the first quarter of 2025. The dividend will be paid on March 7, 2025, to shareholders of record as of January 24, 2025. This marks Pfizer's 345th consecutive quarterly dividend payment, demonstrating the company's commitment to shareholder returns. Chairman and CEO Dr. Albert Bourla emphasized that this dividend increase reflects Pfizer's strong financial performance and disciplined execution.

Positive

• Increased quarterly dividend to $0.43 per share
• 345th consecutive quarterly dividend payment, showing consistent shareholder returns
• Demonstrates financial strength and stability

Negative

• None.

Board of Directors approves increase in quarterly cash dividend to $0.43 per share

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer.

“Our decision to increase our quarterly dividend underscores our strong financial performance, disciplined execution and our commitment to returning value to our shareholders,” said Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice: The information contained in this release is as of December 12, 2024. The Company assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about the Company’s quarterly dividend and capital allocation strategy that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer’s business and prospects, adverse developments in Pfizer’s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Category: Finance

View source version on businesswire.com: https://www.businesswire.com/news/home/20241211645444/en/

Media Contact:

PfizerMediaRelations@Pfizer.com

+1 (212) 733-1226

Investor Contact:

IR@Pfizer.com

+1 (212) 733-4848

Source: Pfizer Inc

FAQ

What is Pfizer's (PFE) new quarterly dividend amount for Q1 2025?

Pfizer's new quarterly dividend amount for Q1 2025 is $0.43 per share.

When will Pfizer (PFE) pay its Q1 2025 dividend?

Pfizer will pay its Q1 2025 dividend on March 7, 2025, to shareholders of record as of January 24, 2025.

How many consecutive quarterly dividends has PFE paid?

Pfizer has paid 345 consecutive quarterly dividends, demonstrating a long history of consistent shareholder returns.

What is the record date for Pfizer's (PFE) Q1 2025 dividend?

The record date for Pfizer's Q1 2025 dividend is January 24, 2025.